Skip to content

The efficacy of Huaiqihuang Granules in children with asymptomatic isolated hematuria: a real-world study

The efficacy of Huaiqihuang Granules in children with asymptomatic isolated hematuria

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023357
Enrollment
Unknown
Registered
2019-05-24
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asymptomatic isolated hematuria

Interventions

treatment group:Huaiqihuang Granules
control group:no intervention

Sponsors

Children's Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: (1) three or more red blood cells per high-power field for urine specimens obtained on three separate occasions on different days (female participants were instructed to avoid testing during menstruation) and recurrent macrohematuria in some patients; (2) no significant proteinuria, with 24-hour urinary excretion of protein less than 0.15 g/day; (3) serum creatinine values within the normal range and without hypertension; (4) no congenital anomalies of the kidney or urinary tract (CAKUT) detected on renal imaging using intravenous pyelographic contrast, B ultrasound or, in some patients, magnetic resonance; (5) being otherwise asymptomatic, with hematuria as the sole finding and not attributable to other known or apparent disease, including systemic lupus erythematosus, urinary tract infections, liver disease, tumors, trauma, drug-induced hematuria, idiopathic hypercalciuria, or rolithiasis.

Exclusion criteria

Exclusion criteria: (1) Hematuria caused by glomerular diseases with clear cause; clinical symptoms such as edema, oliguria, hypertension; family history of hematuria or family history of uremia; (2) Hematuria caused by non-glomerular factors; (3) Have a history of diabetes or check for elevated blood sugar; (4) Those who have participated in other drug clinical trials in the past three months; (5) Immune modulators have been used in the past three months; (6) Can not cooperate with the information registration as required.

Design outcomes

Primary

MeasureTime frame
Hematuria clearance time;Hematuria negative rate;Reduce the level of red blood cells in urine;

Countries

China

Contacts

Public ContactMao Jianhua

Children's Hospital, Zhejiang University School of Medicine

maojh88@zju.edu.cn+86 13516819071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026